The earnings release prompted Waystar’s leadership to raise full-year guidance for the second time in 2025. The company now projects revenue in a range of $1.085 billion to $1.093 billion, compared with prior expectations that began the year in the low-$1 billion area. Adjusted EBITDA is forecast between $451 million and $455 million.
Executives said the revised outlook reflects confidence in the integration of Iodine Software, which closed earlier in the year, and in a sales pipeline that continues to expand across hospitals, physician groups and other care settings. Waystar’s platform helps these organizations manage claims processing, billing, prior authorizations and patient financial engagement, areas that remain focal points for cost containment across the U.S. healthcare system.
According to data from Nasdaq, Waystar shares trade under the ticker symbol “WAY.” The stock is frequently cited by analysts covering digital health as a beneficiary of ongoing shifts toward cloud software and automation in administrative workflows.
The third-quarter performance was driven in part by cost discipline and operating leverage that allowed the company to convert a larger share of revenue into profit. Management emphasized that scale benefits from both organic volume gains and the Iodine Software acquisition are expected to continue in 2026.
Mizuho’s outlook places Waystar among a group of health-technology firms the brokerage views as positioned to capitalize on rising demand for revenue-cycle optimization. The brokerage report did not change its qualitative assessment of Waystar’s competitive position but noted that wider deployment of the company’s AI tools is accelerating customer wins and cross-sell opportunities.
While the brokerage’s commentary focused on Waystar, market commentary around the broader digital-health segment remains mixed. Some observers consider Waystar one of the more compelling publicly traded options in the sector, citing its recurring-revenue model and margin profile. Others point to alternative artificial-intelligence investments they believe offer higher potential returns with lower downside risk. Nevertheless, the company’s improved guidance and Mizuho’s higher price target underscore confidence in near-term growth prospects.
Waystar’s next scheduled financial update is expected with its fourth-quarter and full-year 2025 results, when management plans to provide initial commentary on 2026. Investors will monitor progress on the Iodine Software integration, adoption rates for AI-driven denial management and overall transaction volume—all areas highlighted in the most recent quarterly report.
Crédito da imagem: Bloomberg
